Brachytherapy for prostate cancer Follow-up and management of treatment failures

Urologic Clinics of North America

Volumn 30, Issue 4, 2003, Pages 737-750

  Horwitz, Eric M ^a   Uzzo, Robert G ^b   Miller, Nicole ^c   Theodorescu, Dan ^c,d,e  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD 198; IODINE 125; IRIDIUM 192; ISOTOPE; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

BLADDER DYSFUNCTION; BRACHYTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CRYOSURGERY; DOSIMETRY; EARLY CANCER; FOLLOW UP; HUMAN; IMPLANTATION; IMPOTENCE; LIFE EXPECTANCY; LOW ENERGY RADIATION; MICTURITION DISORDER; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION SICKNESS; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; URETHRA; URETHRA DISEASE; URINARY DYSFUNCTION; URINE RETENTION;

EID: 0344874629     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00059-4     Document Type: Review

References (91)

1. Desai J, Stock RG, Stone NN, et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998;6:135-41.
2. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-82.
3. Merrick GS, Butler WM, Lief JH, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-8.
4. Pasteau D. The radium treatment of cancer of the prostate. Arch Roentgenol Ray 1913;28:396.
5. Watanabe H, Igari D, Tanahashi Y, et al. Transrectal ultrasonotomography of the prostate. J Urol 1975;114:734-9.
6. Holm HH, Juul N, Pedersen JF, et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-6.
7. Wallner K, Chiu-Tsao ST, Roy J, et al. An improved method for computerized tomography-planned transperineal 125iodine prostate implants. J Urol 1991;146:90-5.
8. Wallner K. Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. Oncology 1991;5:115-22.
9. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94.
10. Coblentz TR, Bissonette EA, Williams KR, et al. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis 2002;5:219-25.
11. Krupski T, Bissonette EA, Petroni GR, et al. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. Eur Urol 2003;313:1-6.
12. Krupski T, Petroni GR, Bissonette EA, et al. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000;55:736-42.
13. Fulmer BR, Bissonette EA, Petroni GR, et al. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001;91:2046-55.
14. Miller NL, Bissonette EA, Bahnson R, et al. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer 2003;97:1203-10.
15. Valicenti RK, Bissonette EA, Chen C, et al. Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. J Urol 2002;168:2499-504 [discussion: 2504].
16. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-50.
17. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-7.
18. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999;162:421-6.
19. Nag S, Scaperoth DD, Badalament R, et al. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 1995;45:87-92.
20. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57:263-7.
21. Dattoli M, Wallner K, True L, et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma. Cancer 2003;97:979-83.
22. Ragde H, Korb LJ, Elgamal AA, et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-41.
23. Cha CM, Potters L, Ashley R, et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;45: 391-5.
24. Storey MR, Landgren RC, Cottone JL, et al. Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 1999;43:565-70.
25. Potters L. Permanent prostate brachytherapy: lessons learned, lessons to learn. Oncology 2000;14:981-91.
26. Merrick GS, Butler WM, Galbreath RW, et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41-8.
27. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT- planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47: 1261-6.
28. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
29. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119-24.
30. Merrick GS, Butler WM, Dorsey AT, et al. Rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:667-74.
31. Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. Oncology (Huntingt) 2003;17:52-62 [discussion 62, 67-70, 13].
32. Stock RG, Kao J, Stone NN. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001;165:436-9.
33. Stock RG, Stone NN, Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996;35:267-72.
34. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 2002;60:32-7.
35. Pollack A, Salem N, Ashoori F, et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys 2001; 51:1002-7.
36. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
37. Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
38. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50: 1243-52.
39. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
40. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 2002;60:39-44 [discussion: 44].
41. Grado GL, Larson TR, Balch CS, et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42:289-98.
42. Blasko JC, Grimm PD, Sylsvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-8.
43. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44: 789-99.
44. Stock RG, Stone NN. Permanent radioactive seed implantation in the treatment of prostate cancer. Hematol Oncol Clin North Am 1999;13:489-501.
45. Nag S, Bice W, DeWyngaert K, et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000; 46:221-30.
46. Horwitz EM, Mitra RK, Uzzo RG, et al. Impact of target volume coverage with RTOG 98-05 guidelines for transrectal ultrasound guided permanent I-125 prostate implants. Radiother Oncol 2003;66:173-9.
47. Biggs PJ, Kelley DM. Geometric reconstruction of seed implants using a three-film technique. Med Phys 1983;10:701-4.
48. Roy JN, Wallner KE, Harrington PJ, et al. A CT-based evaluation method for permanent implants: application to prostate. Int J Radiat Oncol Biol Phys 1993;26:163-9.
49. Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:347-53.
50. Moerland MA, Wijrdeman HK, Beersma R, et al. Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997;37:927-33.
51. Dubois DF, Prestidge BR, Hotchkiss LA, et al. Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997;39:1037-41.
52. Narayana V, Roberson PL, Pu AT, et al. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys 1997;37:1181-5.
53. Narayana V, Roberson PL, Winfield RJ, et al. Impact of ultrasound and computed tomography prostate volume registration on evaluation of permanent prostate implants. Int J Radiat Oncol Biol Phys 1997;39:341-6.
54. Prestidge BR, Bice WS, Kiefer EJ, et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;40:1111-5.
55. Waterman FM, Yue N, Corn BW, et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998;41:1069-77.
56. Yue N, Dicker AP, Nath R, et al. The impact of edema on planning 125I and 103Pd prostate implants. Med Phys 1999;26:763-7.
57. Merrick GS, Butler WM, Dorsey AT, et al. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiat Oncol Investig 1998;6:182-90.
58. Horwitz EM, Mitra RK, Uzzo RG, et al. A new 3D non-uniform edema resolution model for prostate following permanent seed implant based upon serial radiography and MRI simulation. American Brachytherapy Society Orlando (FL): 2002;39.
59. Yue N, Chen Z, Peschel R, et al. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. Int J Radiat Oncol Biol Phys 1999;45:1063-72.
60. Lee N, Wuu CS, Brody R, et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:1457-60.
61. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393-9.
62. Crook JM, Perry GA, Robertson S, et al. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995; 45:624-31 [discussion: 631-2].
63. Cox JD, Gallagher MJ, Hammond EH, et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155.
64. Horwitz EM, Vicini FA, Ziaja EL, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Red Journal 1996; 36:565-71.
65. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Red Journal 1997;37:1035-41.
66. Critz FA, Williams WH, Benton JB, et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163:1085-9.
67. Horwitz EM, Uzzo RG, Hanlon AL, et al. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 2003;169:2153-7 [discussion:2157-9].
68. Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000; 18:160-5.
69. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-8.
70. Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002;167: 1310-3.
71. Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Red Journal 2000;48:355-67.
72. Sodee DB, Malguria N, Faulhaber P, et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000;56:988-93.
73. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997;44:213-21.
74. D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20: 4567-73.
75. Corral DA, Pisters LL, von Eschenbach AC. Treatment options for localized recurrence of prostate cancer following radiation therapy. Urol Clin North Am 1996;23:677-84.
76. Fergany A, Kupelian PA, Levin HS, et al. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients. Urology 2000; 56:92-5.
77. Shekarriz B, Upadhyay J, Pontes JE. Salvage radical prostatectomy. Urol Clin North Am 2001; 28:545-53.
78. Russo P. Salvage radical prostatectomy after radiation therapy and brachytherapy. J Endourol 2000;14:385-90.
79. Rogers E, Ohori M, Kassabian VS, et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995;153: 104-10.
80. Amling CL, Lerner SE, Martin SK, et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999;161:857-62.
81. Brenner PC, Russo P, Wood DP, et al. Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation. Br J Urol 1995;75:44-7.
82. Horwitz EM, Hanlon AL, Pinover WH, et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 2001;92:1281-7.
83. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.
84. Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
85. Grado GL. Benefits of brachytherapy as salvage treatment for radiorecurrent localized prostate cancer. Urology 1999;54:204-7.
86. Cox RL, Crawford ED. Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology 1995;45: 932-5.
87. Cohen JK, Miller RJ, Rooker GM, et al. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology 1996; 47:395-401.
88. Miller RJ Jr, Cohen JK, Shuman B, et al. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer 1996;77: 1510-14.
89. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997;157:921-5.
90. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001;165:1937-41.
91. de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000;55:79-84.